Metaclipse Therapeutics Corporation

Atlanta, GA 30316

SBIR Award Summary

Total Number of Awards 2
Total Value of Awards $845K
First Award Date 08/21/13
Most Recent Award Date 09/25/17

Key Personnel

Last Name Name Awards Contact
Pack Christopher D Pack 2

2 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 09/25/17 - 08/31/18

The worldwide incidence of breast cancer is 1.68 million. Triple-negative breast cancers (TNBC) account for ~20% of total breast cancer cases (336,000 worldwide). Annually, over 40,000 new cases of TNBC are diag- nosed in the US alone. The treatment options for TNBC patients are limited. Triple negative breast cancer (TNBC) includes breast cance...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 08/21/13 - 08/20/14

DESCRIPTION (provided by applicant): Triple negative breast cancer (TNBC), which includes tumors lacking estrogen, progesterone, and HER-2 receptor proteins, represents 15-20% of all breast cancer diagnoses in the US, and is one of the most challenging cancers for developing an effective therapy post tumor resection. Even with conventional radia...